scholarly journals Repeated Intraperitoneal -Radioimmunotherapy of Ovarian Cancer in Mice

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Jörgen Elgqvist ◽  
Håkan Andersson ◽  
Holger Jensen ◽  
Helena Kahu ◽  
Sture Lindegren ◽  
...  

The aim of this study was to investigate the therapeutic efficacy of -radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. The study was performed using the monoclonal antibody MX35 F labeled with the -particle emitter .Methods. Nude mice were intraperitoneally inoculated with ~ cells of the cell line NIH:OVCAR-3. Four weeks later 6 groups of animals were given F as a single or as a repeated treatment of up to 6 times ( in each group). The fractionated treatments were given every seventh day. Control animals were treated with unlabeled F (). Eight weeks posttreatment the animals were sacrificed and the presence of macro- and microscopic tumors and ascites was determined.Results. The tumor-free fractions (TFFs) of the animals, defined as the fraction of animals with no macro- and microtumors and no ascites, were 0.17, 0.11, 0.39, 0.44, 0.44, and 0.67 when treated with F once or 2, 3, 4, 5, or 6 times, respectively. Repeated treatment 3 times or more resulted in a significantly higher () TFF than compared to treatment once or twice. The presence of ascites decreased from 15 out of 18 animals in the group given only one treatment to zero for the 2 groups given 5 or 6 fractions. Treatment with unlabeled F resulted in a TFF of zero.Conclusion. Weekly repeated intraperitoneal injections of tolerable amounts of activity of F of up to 6 times produced increased therapeutic efficacy without observed toxicity, indicating a potential increase of the therapeutic index.

2006 ◽  
Vol 33 (8) ◽  
pp. 1065-1072 ◽  
Author(s):  
Jörgen Elgqvist ◽  
Håkan Andersson ◽  
Tom Bäck ◽  
Ingela Claesson ◽  
Ragnar Hultborn ◽  
...  

1989 ◽  
Vol 32 (3) ◽  
pp. 368-370 ◽  
Author(s):  
Alberto Manetta ◽  
Pondichery G. Satyaswaroop ◽  
Thomas Hamilton ◽  
Robert Ozols ◽  
Rodrigue Mortel

1999 ◽  
Vol 4 (4) ◽  
pp. 236-240 ◽  
Author(s):  
Y. Ota ◽  
Ichio Fukasawa ◽  
Hisashi Tokita ◽  
Tomohisa Yamaguchi ◽  
Haruo Yoshino ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 2218 ◽  
Author(s):  
Samantha M. Perez ◽  
Julien Dimastromatteo ◽  
Charles N. Landen ◽  
Kimberly A. Kelly

Cancer-specific plectin (CSP) is a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, including ovarian cancer (OC). Despite its assessable localization, abundance, and functional significance, the therapeutic efficacy of targeting CSP remains unexplored. Here, we generated and investigated the anticancer effects of a novel CSP-targeting monoclonal antibody, 1H11, in OC models. Its therapeutic efficacy as a monotherapy and in combination with chemotherapy was evaluated in vitro using two OC cell lines and in vivo by a subcutaneous ovarian cancer model. 1H11 demonstrated rapid internalization and high affinity and specificity for both human and murine CSP. Moreover, 1H11 induced significant and selective cytotoxicity (EC50 = 260 nM), G0/G1 arrest, and decreased OC cell migration. Mechanistically, these results are associated with increased ROS levels and reduced activation of the JAK2-STAT3 pathway. In vivo, 1H11 decreased Ki67 expression, induced 65% tumor growth inhibition, and resulted in 30% tumor necrosis. Moreover, 1H11 increased chemosensitivity to cisplatin resulting in 60% greater tumor growth inhibition compared to cisplatin alone. Taken together, CSP-targeting with 1H11 exhibits potent anticancer activity against ovarian cancer and is deserving of future clinical development.


2012 ◽  
Vol 39 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Anna M.E. Gustafsson ◽  
Tom Bäck ◽  
Jörgen Elgqvist ◽  
Lars Jacobsson ◽  
Ragnar Hultborn ◽  
...  

1991 ◽  
Vol 34 (3) ◽  
pp. 191-197 ◽  
Author(s):  
Carla F. M. Molthoff ◽  
Herbert M. Pinedo ◽  
Hennie M. M. Schlüper ◽  
Epie Boven

Sign in / Sign up

Export Citation Format

Share Document